메뉴 건너뛰기




Volumn 15, Issue 1, 2016, Pages

Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: A cross-sectional study

Author keywords

Atherogenic dyslipidemia; Diabetes; HDL cholesterol; Residual cardiovascular risk; Silent myocardial ischemia; Triglycerides

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

EID: 84979243153     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0415-4     Document Type: Article
Times cited : (49)

References (41)
  • 1
    • 79954629899 scopus 로고    scopus 로고
    • Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature
    • Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis. 2011;104:178-88.
    • (2011) Arch Cardiovasc Dis , vol.104 , pp. 178-188
    • Valensi, P.1    Lorgis, L.2    Cottin, Y.3
  • 3
    • 0344442364 scopus 로고    scopus 로고
    • Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?
    • Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events? Diabetes Metab. 2003;29:470-6.
    • (2003) Diabetes Metab , vol.29 , pp. 470-476
    • Cosson, E.1    Guimfack, M.2    Paries, J.3    Paycha, F.4    Attali, J.R.5    Valensi, P.6
  • 4
    • 0042668450 scopus 로고    scopus 로고
    • Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia
    • Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care. 2003;26:1313-4.
    • (2003) Diabetes Care , vol.26 , pp. 1313-1314
    • Cosson, E.1    Guimfack, M.2    Paries, J.3    Paycha, F.4    Attali, J.R.5    Valensi, P.6
  • 7
    • 83455265866 scopus 로고    scopus 로고
    • Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients
    • Cosson E, Nguyen MT, Chanu B, Banu I, Chiheb S, Balta C, Takbou K, Valensi P. Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients. Diabetes Care. 2011;34:2101-7.
    • (2011) Diabetes Care , vol.34 , pp. 2101-2107
    • Cosson, E.1    Nguyen, M.T.2    Chanu, B.3    Banu, I.4    Chiheb, S.5    Balta, C.6    Takbou, K.7    Valensi, P.8
  • 8
    • 0037472879 scopus 로고    scopus 로고
    • Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    • Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
    • (2003) N Engl J Med , vol.348 , pp. 383-393
    • Gaede, P.1    Vedel, P.2    Larsen, N.3    Jensen, G.V.4    Parving, H.H.5    Pedersen, O.6
  • 9
    • 84947202868 scopus 로고    scopus 로고
    • Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China
    • Wei Y, Guo H, The E, Che W, Shen J, Hou L, Zhao S, Ye P, Li G, Wang D, Jie Q, Hu D. Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China. Int J Cardiol. 2015;182:469-75.
    • (2015) Int J Cardiol , vol.182 , pp. 469-475
    • Wei, Y.1    Guo, H.2    The, E.3    Che, W.4    Shen, J.5    Hou, L.6    Zhao, S.7    Ye, P.8    Li, G.9    Wang, D.10    Jie, Q.11    Hu, D.12
  • 10
    • 84924333440 scopus 로고    scopus 로고
    • Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
    • Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13:159.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 159
    • Tenenbaum, A.1    Klempfner, R.2    Fisman, E.Z.3
  • 12
    • 84962549699 scopus 로고    scopus 로고
    • Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry
    • Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016;9:100-8.
    • (2016) Circ Cardiovasc Qual Outcomes , vol.9 , pp. 100-108
    • Klempfner, R.1    Erez, A.2    Sagit, B.Z.3    Goldenberg, I.4    Fisman, E.5    Kopel, E.6    Shlomo, N.7    Israel, A.8    Tenenbaum, A.9
  • 13
    • 84924334268 scopus 로고    scopus 로고
    • Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
    • Miselli MA, Nora ED, Passaro A, Tomasi F, Zuliani G. Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovasc Diabetol. 2014;13:135.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 135
    • Miselli, M.A.1    Nora, E.D.2    Passaro, A.3    Tomasi, F.4    Zuliani, G.5
  • 14
    • 84939162770 scopus 로고    scopus 로고
    • Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus
    • Sprandel MC, Hueb WA, Segre A, Ramires JA, Kalil-Filho R, Maranhao RC. Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:107.
    • (2015) Cardiovasc Diabetol , vol.14 , pp. 107
    • Sprandel, M.C.1    Hueb, W.A.2    Segre, A.3    Ramires, J.A.4    Kalil-Filho, R.5    Maranhao, R.C.6
  • 15
    • 84908891471 scopus 로고    scopus 로고
    • LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes
    • Eliasson B, Gudbjornsdottir S, Zethelius B, Eeg-Olofsson K, Cederholm J. LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. Eur J Prev Cardiol. 2014;21:1420-8.
    • (2014) Eur J Prev Cardiol , vol.21 , pp. 1420-1428
    • Eliasson, B.1    Gudbjornsdottir, S.2    Zethelius, B.3    Eeg-Olofsson, K.4    Cederholm, J.5
  • 16
    • 84908029477 scopus 로고    scopus 로고
    • The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR)
    • Eeg-Olofsson K, Gudbjornsdottir S, Eliasson B, Zethelius B, Cederholm J. The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract. 2014;106:136-44.
    • (2014) Diabetes Res Clin Pract , vol.106 , pp. 136-144
    • Eeg-Olofsson, K.1    Gudbjornsdottir, S.2    Eliasson, B.3    Zethelius, B.4    Cederholm, J.5
  • 17
    • 0031567848 scopus 로고    scopus 로고
    • (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus
    • Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol. 1997;79:134-9.
    • (1997) Am J Cardiol. , vol.79 , pp. 134-139
  • 19
    • 0036676005 scopus 로고    scopus 로고
    • Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism
    • Gazzaruso C, Garzaniti A, Giordanetti S, Falcone C, De Amici E, Geroldi D, Fratino P. Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care. 2002;25:1418-24.
    • (2002) Diabetes Care , vol.25 , pp. 1418-1424
    • Gazzaruso, C.1    Garzaniti, A.2    Giordanetti, S.3    Falcone, C.4    Amici, E.5    Geroldi, D.6    Fratino, P.7
  • 20
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • The ACCORD study group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
    • (2010) N Engl J Med , vol.362 , pp. 1563-1574
  • 21
    • 77956341685 scopus 로고    scopus 로고
    • Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control
    • Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757-63.
    • (2010) Am J Cardiol , vol.106 , pp. 757-763
    • Carey, V.J.1    Bishop, L.2    Laranjo, N.3    Harshfield, B.J.4    Kwiat, C.5    Sacks, F.M.6
  • 25
    • 0035941990 scopus 로고    scopus 로고
    • Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study
    • Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet. 2001;357:905-10.
    • (2001) Lancet. , vol.357 , pp. 905-910
  • 26
    • 84959114847 scopus 로고    scopus 로고
    • Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
    • Arbel Y, Klempfner R, Erez A, Goldenberg I, Benzekry S, Shlomo N, Fisman EZ, Tenenbaum A. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovasc Diabetol. 2016;15:11.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 11
    • Arbel, Y.1    Klempfner, R.2    Erez, A.3    Goldenberg, I.4    Benzekry, S.5    Shlomo, N.6    Fisman, E.Z.7    Tenenbaum, A.8
  • 28
    • 77954734498 scopus 로고    scopus 로고
    • Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i)
    • Fruchart JC, Sacks FM, Hermans MP. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin. 2010;26:1793-7.
    • (2010) Curr Med Res Opin , vol.26 , pp. 1793-1797
    • Fruchart, J.C.1    Sacks, F.M.2    Hermans, M.P.3
  • 29
    • 80054682430 scopus 로고    scopus 로고
    • Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
    • Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011;28:1343-51.
    • (2011) Diabet Med , vol.28 , pp. 1343-1351
    • Leiter, L.A.1    Lundman, P.2    Silva, P.M.3    Drexel, H.4    Junger, C.5    Gitt, A.K.6
  • 31
    • 79951774866 scopus 로고    scopus 로고
    • Lipids, lipid-lowering therapy and diabetes complications
    • Valensi P, Picard S. Lipids, lipid-lowering therapy and diabetes complications. Diabetes Metab. 2011;37:15-24.
    • (2011) Diabetes Metab , vol.37 , pp. 15-24
    • Valensi, P.1    Picard, S.2
  • 33
  • 34
    • 84995495876 scopus 로고    scopus 로고
    • Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease
    • Mahalle N, Garg MK, Naik SS, Kulkarni MV. Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease. Indian J Endocrinol Metab. 2014;18:48-55.
    • (2014) Indian J Endocrinol Metab , vol.18 , pp. 48-55
    • Mahalle, N.1    Garg, M.K.2    Naik, S.S.3    Kulkarni, M.V.4
  • 35
    • 14844294788 scopus 로고    scopus 로고
    • Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study
    • Faglia E, Manuela M, Antonella Q, Michela G, Vincenzo C, Maurizio C, Roberto M, Alberto M. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J. 2005;149:e1-6.
    • (2005) Am Heart J , vol.149 , pp. e1-e6
    • Faglia, E.1    Manuela, M.2    Antonella, Q.3    Michela, G.4    Vincenzo, C.5    Maurizio, C.6    Roberto, M.7    Alberto, M.8
  • 37
    • 84914690513 scopus 로고    scopus 로고
    • Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial
    • Muhlestein JB, Lappe DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, Vavere AL, Anderson JL. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014;312:2234-43.
    • (2014) JAMA , vol.312 , pp. 2234-2243
    • Muhlestein, J.B.1    Lappe, D.L.2    Lima, J.A.3    Rosen, B.D.4    May, H.T.5    Knight, S.6    Bluemke, D.A.7    Towner, S.R.8    Le, V.9    Bair, T.L.10    Vavere, A.L.11    Anderson, J.L.12
  • 38
    • 73949113394 scopus 로고    scopus 로고
    • Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    • Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TM, Laakso M, Kesäniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010;31:92-9.
    • (2010) Eur Heart J , vol.31 , pp. 92-929
    • Burgess, D.C.1    Hunt, D.2    Li, L.3    Zannino, D.4    Williamson, E.5    Davis, T.M.6    Laakso, M.7    Kesäniemi, Y.A.8    Zhang, J.9    Sy, R.W.10    Lehto, S.11    Mann, S.12    Keech, A.C.13
  • 39
    • 85048354213 scopus 로고    scopus 로고
    • Combination lipid therapy in type 2 diabetes
    • Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692-4 (author reply 4-5).
    • (2010) N Engl J Med , vol.363 , pp. 692-694
    • Sacks, F.M.1    Carey, V.J.2    Fruchart, J.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.